Shire reported positive topline results with SHP465 (triple-bead mixed amphetamine salts) in 275 adults aged 18-55 years with Attention-Deficit/Hyperactivity Disorder (ADHD), the last set of data required ahead of Class 2 Resubmission of an NDA with the US FDA by the end of 2016
The product is slated for potential US approval in the second half of 2017.





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
